RemeGen Co (HKSE:09995) Cash, Cash Equivalents, Marketable Securities : HK$775.6 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Cash, Cash Equivalents, Marketable Securities?

RemeGen Co's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 (HK$1,510.26 Mil) to Sep. 2023 (HK$0.00 Mil) but then increased from Sep. 2023 (HK$0.00 Mil) to Dec. 2023 (HK$775.57 Mil).

RemeGen Co's annual cash, cash equivalents, marketable securities increased from Dec. 2021 (HK$2,151.17 Mil) to Dec. 2022 (HK$2,310.68 Mil) but then declined from Dec. 2022 (HK$2,310.68 Mil) to Dec. 2023 (HK$775.57 Mil).

RemeGen Co Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for RemeGen Co's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Cash, Cash Equivalents, Marketable Securities Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

38.44

3,281.90

2,151.17

2,310.68

775.57

RemeGen Co Quarterly Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial									2,310.68	1,510.26	-	775.57	-

RemeGen Co Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

RemeGen Co (HKSE:09995) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

RemeGen Co Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co (HKSE:09995) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

REGMF:USA REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

http://www.remegen.com

RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).

Executives

Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Rongchang Holding Group Ltd.	2103 Interests held jointly with another person
Yantai Rongda Venture Capital Center (limited Partnership)	2103 Interests held jointly with another person
Yang Minhua	2103 Interests held jointly with another person
Xiong Xiaobin	2103 Interests held jointly with another person
Wen Qingkai	2103 Interests held jointly with another person
Wei Jianliang	2103 Interests held jointly with another person
Wang Xudong	2103 Interests held jointly with another person
Wang Weidong	2201 Interest of corporation controlled by you
Wang Liqiang	2103 Interests held jointly with another person
I-nova Limited	2101 Beneficial owner
Lin Jian	2103 Interests held jointly with another person
Fang Jianmin	2103 Interests held jointly with another person
Deng Yong	2103 Interests held jointly with another person
Morgan Stanley	2201 Interest of corporation controlled by you

RemeGen Co (HKSE:09995) Headlines

No Headlines